Clade Therapeutics
Grant is an experienced cell engineer with deep expertise in the development of engineered cell medicines for oncology. Prior to Clade, Grant led several programs at Editas Medicine that were focused on the development of CRISPR gene-edited T cells and iPSC-derived NK cells. As the 8th hire in 2014, he was also an integral part of building a strong company culture that supported the transition of Editas from a 10-person, series A startup to a publicly traded, clinical stage company.
Grant was awarded his Ph.D. from the Department of Medical Biophysics at the University of Toronto and received his Bachelor of Science from McGill University in Montreal, majoring in Microbiology and Immunology. After his doctorate, Grant was a NIH postdoctoral fellow in the laboratory of Rudolf Jaenisch at the Whitehead Institute for Biomedical Research where he studied epigenetics in stem cells, cancer and cellular reprogramming.
This person is not in any offices
Clade Therapeutics
Clade Therapeutics is a well-funded cell therapy company developing novel cell-based medicines for the treatment of cancer and other devastating diseases. The company, located in the heart of Cambridge was recently launched by an exceptional group of academic leaders and successful bioentrepreneurs converging stem cell biology, immunology, regenerative medicine, and gene editing into the next-generation of stem cell-derived medicines.